Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...

Eric Joseph, an analyst from J.P. Morgan, maintained the Hold rating on Vir Biotechnology (VIR – Research Report). The associated price target ...

An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

The gene neuropilin2 encodes a receptor involved in cell-cell interactions in the brain and plays a key role in regulating ...

A study published today in the journal Nature by researchers at Columbia University described a new medical AI model that ...

Imagine having a digital carbon copy of yourself that physicians could use to predict long-term risks for disease, assess how your body may respond to treatment, and simulate surgeries in advance. A ...

The global artificial intelligence in clinical trials market, valued at US$1.20 billion in 2023, is forecasted to grow at a ...

US-based Halia Therapeutics’ new therapy will be put to a six-month-long trial that will involve 60 patients with type 2 ...

A multidisciplinary team of University of Miami researchers studying factors associated with health outcomes and disease risk in the Hispanic community has received a $21 million grant from the ...

As a wellness writer who spends a bit too much time analyzing indigent lists and scrolling on TikTok, there’s hardly anything ...

NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated high complete response rates ...

IROS and Halia Therapeutics’ clinical trial will explore a promising new therapy for obesity, specifically designed to ...